| Literature DB >> 29148315 |
Joshua D Bernstock1,2, Wei Yang3, Daniel G Ye1, Yuntian Shen3, Stefano Pluchino2, Yang-Ja Lee1, John M Hallenbeck1, Wulf Paschen3,4.
Abstract
Post-translational protein modification by small ubiquitin-like modifier (SUMO) regulates a myriad of homeostatic and stress responses. The SUMOylation pathway has been extensively studied in brain ischemia. Convincing evidence is now at hand to support the notion that a major increase in levels of SUMOylated proteins is capable of inducing tolerance to ischemic stress. Therefore, the SUMOylation pathway has emerged as a promising therapeutic target for neuroprotection in the face of brain ischemia. Despite this, it is prudent to acknowledge that there are many key questions still to be addressed in brain ischemia related to SUMOylation. Accordingly, herein, we provide a critical review of literature within the field to summarize current knowledge and in so doing highlight pertinent translational implications of the SUMOylation pathway in brain ischemia.Entities:
Keywords: Brain ischemia; SUMOylation; cell-therapy; drug repurposing; hypothermia; neuroprotection; stroke
Mesh:
Year: 2017 PMID: 29148315 PMCID: PMC5757445 DOI: 10.1177/0271678X17742260
Source DB: PubMed Journal: J Cereb Blood Flow Metab ISSN: 0271-678X Impact factor: 6.200